专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009014835A2 MODIFIED TOXINS 审中-公开
标题翻译：改性毒素
公开(公告)号：WO2009014835A2
公开(公告)日：2009-01-29
申请号：PCT/US2008/067682
申请日：2008-06-20
申请人： ANGELICA THERAPEUTICS, INC. , DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , RUST, Alyson, Jane , KEEN, Simon
发明人： DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , RUST, Alyson, Jane , KEEN, Simon
IPC分类号： A61K39/02
CPC分类号： C07K14/34 , A61K38/16 , A61K39/0011 , A61K39/39 , A61K47/6415 , A61K47/642 , A61K2039/5156 , A61K2039/55533 , A61K2039/55544
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non- malignant disease.
摘要翻译：本申请涉及具有降低的免疫原性和减少与血管内皮细胞或血管内皮细胞结合的修饰毒素的组合物，从而降低血管渗漏综合征的发生率。还提供了来自修饰的白喉毒素的多肽毒素体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及来自修饰的白喉毒素的多肽毒候球体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基和未修饰的天然白喉毒素的至少一个VLS基序的至少一个氨基酸残基。另一方面涉及融合蛋白，其包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段。另一方面涉及使用修饰的白喉毒素治疗恶性疾病或非恶性疾病。

2. 发明申请

WO2009014835A3 MODIFIED TOXINS 审中-公开
标题翻译：修饰的毒素
公开(公告)号：WO2009014835A3
公开(公告)日：2009-05-07
申请号：PCT/US2008067682
申请日：2008-06-20
申请人： ANGELICA THERAPEUTICS INC , DAVIS CLAUDE GEOFFREY , DATTA DEEPSHIKHA , BAKER MATTHEW PAUL , RUST ALYSON JANE , KEEN SIMON
发明人： DAVIS CLAUDE GEOFFREY , DATTA DEEPSHIKHA , BAKER MATTHEW PAUL , RUST ALYSON JANE , KEEN SIMON
IPC分类号： C07K14/00
CPC分类号： C07K14/34 , A61K38/16 , A61K39/0011 , A61K39/39 , A61K47/6415 , A61K47/642 , A61K2039/5156 , A61K2039/55533 , A61K2039/55544
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non- malignant disease.
摘要翻译：本申请涉及表现出降低的免疫原性和降低的与血管内皮或血管内皮细胞的结合的修饰毒素的组合物，由此降低血管渗漏综合征的发病率。还提供了来自修饰的白喉毒素的多肽毒素，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一个方面涉及来自修饰的白喉毒素的多肽的毒素，其中修饰在未修饰的天然白喉毒素的至少一个T细胞表位的至少一个氨基酸残基和至少一个VLS基序的至少一个氨基酸残基。另一方面涉及包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段的融合蛋白。另一方面涉及修饰的白喉毒素用于治疗恶性疾病或非恶性疾病的用途。

3. 发明申请

WO2007099341A1 T CELL ASSAYS 审中-公开
标题翻译： T细胞测定
公开(公告)号：WO2007099341A1
公开(公告)日：2007-09-07
申请号：PCT/GB2007/000736
申请日：2007-03-02
申请人： ANTITOPE LIMITED , BAKER, Mathew , CARR, Francis, J. , RUST, Alyson , DAVIES, Laura
发明人： BAKER, Mathew , CARR, Francis, J. , RUST, Alyson , DAVIES, Laura
IPC分类号： G01N33/50
CPC分类号： G01N33/505 , G01N2333/70517 , G01N2333/70596
摘要： The present invention relates to novel T cell assay methods, in particular where T cell responses to test antigens are increased by removal of regulatory T cells. Novel assays where the timing of incubation with antigens or other samples is varied in order to optimize detection of T cell responses are described. The invention has particular application for measurement of human T cell responses to pharmaceuticals, allergens, irritants or other substances.
摘要翻译：本发明涉及新型T细胞测定方法，特别是通过去除调节性T细胞来增加对测试抗原的T细胞应答的增加。描述了与抗原或其他样品的温育时间变化以优化T细胞应答检测的新型测定法。本发明特别适用于测量人类T细胞对药物，变应原，刺激物或其他物质的反应。

4. 发明申请

WO2009014835A9 MODIFIED TOXINS 审中-公开
标题翻译：改性毒素
公开(公告)号：WO2009014835A9
公开(公告)日：2014-03-20
申请号：PCT/US2008067682
申请日：2008-06-20
申请人： ANGELICA THERAPEUTICS INC , DAVIS CLAUDE GEOFFREY , DATTA DEEPSHIKHA , BAKER MATTHEW PAUL , RUST ALYSON JANE , KEEN SIMON
发明人： DAVIS CLAUDE GEOFFREY , DATTA DEEPSHIKHA , BAKER MATTHEW PAUL , RUST ALYSON JANE , KEEN SIMON
IPC分类号： C07K14/00
CPC分类号： C07K14/34 , A61K38/16 , A61K39/0011 , A61K39/39 , A61K47/6415 , A61K47/642 , A61K2039/5156 , A61K2039/55533 , A61K2039/55544
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non- malignant disease.
摘要翻译：本申请涉及具有降低的免疫原性和减少与血管内皮细胞或血管内皮细胞结合的修饰毒素的组合物，从而降低血管渗漏综合征的发生率。还提供了来自修饰的白喉毒素的多肽毒素体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及来自修饰的白喉毒素的多肽毒候球体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基和未修饰的天然白喉毒素的至少一个VLS基序的至少一个氨基酸残基。另一方面涉及融合蛋白，其包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段。另一方面涉及使用修饰的白喉毒素治疗恶性疾病或非恶性疾病。

5. 发明申请

WO2009110944A1 MODIFIED TOXINS 审中-公开
标题翻译：改性毒素
公开(公告)号：WO2009110944A1
公开(公告)日：2009-09-11
申请号：PCT/US2008/086858
申请日：2008-12-15
申请人： ANGELICA THERAPEUTICS, INC. , DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , KEEN, Simon , RUST, Alyson, Jane
发明人： DAVIS, Claude, Geoffrey , DATTA, Deepshikha , BAKER, Matthew, Paul , KEEN, Simon , RUST, Alyson, Jane
IPC分类号： A61K38/16 , A61P37/06 , A61K39/395
CPC分类号： C07K14/34 , A61K38/00 , C07K2319/035
摘要： The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
摘要翻译：本申请涉及具有降低的免疫原性和减少与血管内皮细胞或血管内皮细胞结合的修饰毒素的组合物，从而降低血管渗漏综合征的发生率。还提供了来自修饰的白喉毒素的多肽毒素体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。另一方面涉及来自修饰的白喉毒素的多肽毒候球体，其中修饰在至少一个T细胞表位的至少一个氨基酸残基和未修饰的天然白喉毒素的至少一个VLS基序的至少一个氨基酸残基。另一方面涉及融合蛋白，其包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段。另一方面涉及使用修饰的白喉毒素治疗恶性疾病或非恶性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式